美国生物制药公司托尼克斯制药控股公司（Tonix Pharmaceuticals Holding Co，股票代码：TNXP）周五盘前大涨7.28%，引发市场广泛关注。这一显著涨幅出现在公司发布第二季度财报后，尽管业绩不及预期，但投资者似乎对公司的长期发展前景保持乐观。
根据公司最新发布的财报，截至6月30日的季度调整后每股亏损为3.86美元，高于分析师预期的3.21美元亏损。公司营收为200万美元，同比下降9.5%，也低于分析师预期的243万美元。尽管季度业绩表现不佳，托尼克斯制药的股价本季度已累计上涨71.1%，今年迄今为止更是上涨了86.7%，显示出投资者对公司的持续信心。
值得注意的是，尽管季度业绩不及预期，分析师仍对托尼克斯制药保持积极态度。目前，分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为65.00美元，较前一交易日收盘价高出约5.3%。这种乐观情绪可能是推动股价在财报发布后继续上涨的主要原因。投资者似乎更加关注公司的长期发展潜力，而非短期业绩波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.